Newsoara Biopharma Co., Ltd.

5 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	NCT ID
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer	DNA Virus Infections, Infections, Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, lung disorder, lung neoplasm, milker's nodule, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm, vaccinia, viral infectious disease	Recruiting	Phase 2	2026-06-04	NCT06463665
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer	Metastatic Castration-Resistant Prostate Cancer	Recruiting	Phase 2	2026-05-08	NCT04986423
Evaluation of the Safety, Tolerability and Pharmacokinetics of HY8931 in Healthy Adult Participants	Healthy	Recruiting	Phase 1	2026-03-11	NCT07281703
Evaluation of the Safety, Tolerability and Pharmacokinetics of HY6725 in Healthy Adult Participants	Healthy	Recruiting	Phase 1	2026-03-11	NCT07262281
HY1272 in Patients With Locally Advanced or Metastatic Solid Tumors or Locally Advanced or Metastatic EGFRm+ NSCLC	Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm	Not yet recruiting	Phase 1	2024-01-23	NCT06218940

Clinical trials